14β-Chlorocinnamoylamino derivatives of metopon: Long-term μ-opioid receptor antagonists

European Journal of Pharmacology

Volumn 320, Issue 2-3, 1997, Pages 121-129

  McLaughlin, Jay P ^a   Sebastian, Alice ^b   Archer, Sydney ^b   Bidlack, Jean M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Research Rensselaer Polytechnic Institute   (United States)

Author keywords

Endorphin receptor; (Irreversible antagonist); (Mouse); Analgesia; Cinnamoylamino group; Morphine derivative

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 5BETA METHYL 14BETA(4 CHLOROCINNAMOYLAMINO) 7,8 DIHYDROMORPHINONE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; MORPHINE; MORPHINE DERIVATIVE; N CYCLOPROPYL METHYL 5BETA METHYL 14BETA(4 CHLOROCINNAMOYLAMINO) 7,8 DIHYDROMORPHINONE; OPIATE; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BINDING SITE; BRAIN MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; TAIL FLICK TEST;

ANALGESICS; ANIMALS; BENZENEACETAMIDES; BINDING, COMPETITIVE; CATTLE; CORPUS STRIATUM; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALINS; KINETICS; MALE; MICE; MICE, INBRED ICR; MORPHINANS; NARCOTIC ANTAGONISTS; NOCICEPTORS; PAIN MEASUREMENT; PYRROLIDINES; RECEPTORS, OPIOID, MU; TRITIUM;

EID: 0031565277     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00904-1     Document Type: Article

References (42)

1. Aceto, M.D., E.R. Bowman, E.L. May, L.S. Harris, J.H. Woods, C.B. Smith, F. Medzihradsky and A.E. Jacobson, 1989, Very long-acting narcotic antagonists: the 14β-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives, Arzneim.-Forsch./Drug Res. 39, 570.
2. Archer, S., A. Seyed-Mozaffari, Q. Jiang and J.M. Bidlack, 1994, 14α,14′β-[Dithiobis[2-oxo-2,1-ethanediyl)imino]]bis[(7,8-dihydromorphinone) and 14α,14′β-[dithiobis[2-oxo-2,1-ethanediyl)imino]]bis[7,8-dihydro-N-(cyclopropylmethyl)normorphinone]: chemistry and opioid binding properties, J. Med. Chem. 37, 1578.
3. Bidlack, J.M, D.K. Frey, R.K. Kaplan, A. Seyed-Mozaffari and S. Archer, 1990, Affinity labeling of μ opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone, Mol. Pharmacol. 37, 50.
4. 3H]-14-β-(bromoacetamido)-7,8-dihydromorphine, Biochemistry 32, 6703.
5. Bradford, M.M., 1976, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem. 72, 248.
6. Burke, T.F., J.H. Woods, J.W. Lewis and F. Medzihradsky, 1994, Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice, J. Pharmacol. Exp. Ther. 271, 715.
7. Chen, C., J.C. Xue, J. Zhu, Y.W. Chen, S. Kunapuli, J.K. De Riel, L. Yu and L.Y. Liu-Chen, 1995, Characterization of irreversible binding of β-funaltrexamine to the cloned rat μ opioid receptor, J. Biol. Chem. 270, 17866.
8. 3H]β-funaltrexamine covalent binding in the cloned rat μ opioid receptor, J. Biol. Chem. 271, 21422.
9. 50) of an enzymatic reaction, Biochem. Pharmacol. 22, 3099.
10. Childers, S.R., 1984, Interaction of opiate receptor binding sites and guanine nucleotide regulatory sites: selective protection from N-ethylmaleimide, J. Pharmacol. Exp. Ther. 230, 684.
11. Comer, S.D., T.F. Burke, J.W. Lewis and J.H. Woods, 1992, Clocinnamox: a novel, systemically-active, irreversible opioid antagonist, J. Pharmacol. Exp. Ther. 262, 1051.
12. Derrick, I., J.W. Lewis, H.A. Moynihan, J. Broadbear and J.H. Woods, 1996, Potential irreversible ligands for opioid receptors. Cinnamoyl derivatives of β-naltrexamine, J. Pharm. Pharmacol. 48, 192.
13. Haley, T.J. and W.G. McCormick, 1957, Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse, Br. J. Pharmacol. Chemother. 12, 12.
14. Hellerbach, J., O. Schnider, H. Besendorf and B. Pellmont, 1966, Synthetic Analgesics, Part IIA, Morphinans, in: International Series of Monographs in Organic Chemistry, eds. D.H.R. Barton and W. Von Doering (Pergamon Press, Oxford) p. 74.
15. 2BAMO), J. Pharmacol. Exp. Ther. 262, 1021.
16. Jiang, Q., A. Sebastian, S. Archer and J.M. Bidlack, 1993a, 5β-Methyl-14β-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting μ-opioid receptor antagonist devoid of agonist properties, Eur. J. Pharmacol. 230, 129.
17. Jiang, Q., A. Seyed-Mozaffari, S. Archer and J.M. Bidlack, 1993b, Pharmacological study of 14β-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normorphinone (N-CPM-TAMO), J. Pharmacol. Exp. Ther. 264, 1993.
18. Jiang, Q., A. Sebastian, S. Archer and J.M. Bidlack, 1994, 5β-Methyl-14β-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5β-methyl-14β-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: mu-selective irreversible opioid antagonists, J. Pharmacol. Exp. Ther. 268, 1107.
19. Jiang, Q., A. Seyed-Mozaffari, A. Sebastian, S. Archer and J.M. Bidlack, 1995, Preventing morphine antinociception tolerance by irreversible mu opioid antagonists before the onset of their antagonism, J. Pharmacol. Exp. Ther. 273, 680.
20. Joseph, D.B. and J.M. Bidlack, 1994, The κ-opioid receptor expressed on the mouse lymphoma cell line R1.1 contains a sulfhydryl group at the binding site, Eur. J. Pharmacol. 267, 1.
21. Kong, H., K. Raynor, H. Yano, J. Takeda, G.I. Bell and T. Resine, 1994, Agonists and antagonists bind to different domains of the cloned κ opioid receptor, Proc. Natl. Acad. Sci. USA 91, 8042.
22. Law, P.-Y., D.S. Hom and H.H. Loh, 1983, Opiate receptor down-regulation and desensitization in neuroblastoma×glioma NG108-15 hybrid cells are two separate cellular adaptation processes, Mol. Pharmacol. 24, 413.
23. Lewis, J., C. Smith, P. McCarty, D. Walter, R. Kobylecki, M. Myers, A. Haynes, C. Lewis and K. Waltham, 1988, New 14-aminomorphinones and codeinones, NIDA Res. Monogr. 90, 136.
24. 3H]β-funaltrexamine, Mol. Pharmacol. 32, 321.
25. McLaughlin, J.P., D. Nowak, A. Sebastian, A.G. Schultz, S. Archer and J.M. Bidlack, 1995, Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors, Eur. J. Pharmacol. 294, 201.
26. McLaughlin, J.P., A. Sebastian, S. Archer and J.M. Bidlack, 1994, 14β-Chlorocinnamoylamino derivatives of metopon interact differentially with the mu opioid receptor, Regul. Pept. 54, 187.
27. 3H]N-CPM-CACO, NIDA Res. Monogr.
28. Munson, P.J. and D. Rodbard, 1980, LIGAND: a versatile computerized approach for characterization of ligand-binding systems, Anal. Biochem. 107, 220.
29. Pasternak, G.W. and E.F. Hahn, 1980, Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones, J. Med. Chem. 23, 674.
30. Pasternak, G.W., H.A. Wilson and S.H. Snyder, 1975, Differential effects of protein-modifying reagents on receptor binding of opiate agonists and antagonists, Mol. Pharmacol. 11, 340.
31. Portoghese, P.S., D.L. Larson, L.M. Sayre, D.S. Fries and A.E. Takemori, 1980, A novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activities, J. Med. Chem. 23, 233.
32. Rice, K.C., A.E. Jacobson, T.R. Burke Jr., B.S. Bajwa, A.R. Streaty and W.A. Klee, 1983, Irreversible ligands with high selectivity towards δ or μ opiate receptors, Science 220, 314.
33. Sebastian, A., J.M. Bidlack, Q. Jiang, D. Deecher, M. Teitler, S.D. Glick and S. Archer, 1993, 14β-[(p-Nitrocinnamoyl)amino]morphinones, 14β-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones and their codeinone analogues: synthesis and receptor activity, J. Med. Chem. 36, 3154.
34. 3H-etorphine to rat brain homogenate, Proc. Natl. Acad. Sci. USA 70, 1947.
35. Tallarida, R.J. and R.B. Murray, 1986, Manual of Pharmacologic Calculation with Computer Programs, 2nd edn. (Springer-Verlag, New York).
36. Thompson, R.C., A. Mansour, H. Akil and S.J. Watson, 1993, Cloning and pharmacological characterization of a rat μ opioid receptor, Neuron 11, 903.
37. Vaught, J.L. and A.E. Takemori, 1979, Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence, J. Pharmacol. Exp. Ther. 208, 86.
38. Ward, S.J., P.S. Portoghese and A.E. Takemori, 1982, Pharmacological characterization in vivo of the novel opiate, β-funaltrexamine, J. Pharmacol. Exp. Ther. 220, 494.
39. Ward, S.J., D.S. Fries, D.L. Larson, P.S. Portoghese and A.E. Takemori, 1985, Opioid receptor binding characteristics of the non-equilibrium μ-antagonist, β-funaltrexamine (β-FNA), Eur. J. Pharmacol. 107, 323.
40. Xu, J.Y., A. Seyed-Mozaffari, S. Archer and J.M. Bidlack, in press, N-Cyclobuthylmethyl analogue of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term mu-selective irreversible opioid antagonist, J. Pharmacol. Exp. Ther.
41. Xue, J.C., C. Chen, J. Zhu, S. Kunapuli, J.K. DeRiel, L. Yu and L.Y. Liu-Chen, 1995, The third extracellular loop of the μ opioid receptor is important for agonist selectivity, J. Biol. Chem. 270, 12977.
42. 3H]-clocinnamox binding in mouse brain membranes, Analgesia 1, 874.